Last reviewed · How we verify
Labor pain — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Opana Er | OXYMORPHONE | Endo | Opioid Agonist | Mu-type opioid receptor | 1959-01-01 | |
| Meperidine Hydrochloride Preservative Free | Meperidine Hydrochloride | Pfizer | Opioid Agonist | Mu-type opioid receptor | 1942-01-01 | |
| Pethidin | Pethidin | Ain Shams University | Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Labor pain
- Ain Shams University · 1 drug in Labor pain
- Endo · 1 drug in Labor pain
- Pfizer · 1 drug in Labor pain
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Labor pain:
- Labor pain treatment updates — RSS
- Labor pain treatment updates — Atom
- Labor pain treatment updates — JSON
Cite this brief
Drug Landscape (2026). Labor pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/labor-pain. Accessed 2026-06-10.
Related
- Labor pain full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing